Efruxifermin, an experimental drug mimicking fibroblast growth factor 21 (FGF21), is being investigated in phase 3 SYNCHRONY trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)....
Jennifer Geremia,
MSPAS, PA-C
Physician Associate, Brigham and Women’s Hospital and Teaching Hospital of Harvard Medical School
During recent decades, the metabolic dysfunction-associated steatohepatitis (MASH) field has witnessed several paradigm shifts, including the recognition of liver fibrosis...
NASH Becoming Leading Cause for Liver Transplantation
Nonalcoholic steatohepatitis (NASH) is rapidly becoming the leading indication for liver transplantation in the US. However, patients with NASH face...
In 2024, resmetirom (MGL-3196) became the first FDA-approved drug for MASH, demonstrating significant efficacy in resolving MASH without worsening fibrosis...
Top Therapies for Reducing Hepatic Fat in MASH Identified in Meta-Analysis
Metabolic dysfunction–associated steatohepatitis (MASH) is a major contributor to liver disease, and reducing hepatic fat is critical for improving patient...
